The report of influenza medication market by Product (Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine, Inosine) Distribution Channel (Hospitals, Clinics, Pharmacies and Region (Asia Pacific, North America, Europe, Latin America, and Middle East Africa) is expected to reach US$ XX Bn by 2027, at a CAGR of XX% during a forecast period.
Influenza medication contain antiviral drugs that are used for the treatment of Influenza. Influenza (flu), is a viral infection that attacks your respiratory system such as your nose, throat and lungs. The common symptoms of the disorder are cold, cough, fever, and sore throat, which can be severe or mild. The unmet medical needs within the annual influenza epidemics along with strong R&D focus resulting in new and advanced treatments and drugs, and favorable policies for treatment and prevention of influenza by the government in developed regions. These are the major drivers in the growth of influenza medication market. Patent expiry of key drugs and entry of generics and Side effects of anti-influenza drug therapy are hamper the market growth globally.
Pharmacies segment is expected to grow at the highest XX% CAGR during the forecast period.
In 2018, the pharmacies segment held a significant share in the market. And continue this trend during the forecast period due to the growing pharmacy stores around the world. Besides this, the market is likely to witness beneficial prospects in the hospitals segment. Incidence and prevalence of flu are gradually increasing across the world.
The North America dominated the influenza medication market in 2018
In 2018, North America held the largest share of the Influenza medication market. The U.S. lead the Influenza medication market in North America owing to increasing acceptance of advanced and high-cost drug therapies, increased treatment rate, and favorable reimbursement policies in the country. In terms of both value and volume, the Asia Pacific region will record a significant CAGR of XX% during the forecasted period due to major contribution from developing countries, availability of low cost treatment and availability of better health care facilities. China and India are highly populated countries with the maximum number of influenza patients making them major contributor to the growth of the market in Asia Pacific.
Key players operating the influenza medication market are Daiichi Sankyo Company, GlaxoSmithKline plc, Natco Pharma, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., Mylan, Inc., Emirates SkyCargo, Sanofi, Merck, Pfizer, Novarties, Seqirus
Maximize Market Research, a global market research firm with a dedicated team of specialists and data has carried out extensive research about the influenza medication market. The report encompasses the market by different segments and region, providing an in-depth analysis of the overall industry ecosystem, useful for making an informed strategic decision by the key stakeholders in the industry. Importantly, the report delivers forecasts and share of the market, further giving an insight into the market dynamics, and future opportunities that might exist in the influenza medication market. The driving forces, as well as considerable restraints, have been explained in depth. in addition to this, competitive landscape describing the strategic growth of the competitors have been taken into consideration for enhancing market know-how of our clients and at the same time explain influenza medication market positioning of competitors.
Browse the market data Tables and Figures spread through a comprehensive research report and in-depth TOC on “Influenza Medication Market”
Contact:
MAXIMIZE MARKET RESEARCH PVT. LTD.
Omkar Heights,
ManikBaug, Vadgaon Bk,
Sinhagad Road, Pune – 411051, Maharashtra, India.
+91 9607195908